Advances in the computational landscape for repurposed drugs against COVID-19

被引:18
|
作者
Aronskyy, Illya [1 ]
Masoudi-Sobhanzadeh, Yosef [2 ]
Cappuccio, Antonio [1 ]
Zaslavsky, Elena [1 ]
机构
[1] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA
[2] Tabriz Univ Med Sci, Res Ctr Pharmaceut Nanotechnol, Biomed Inst, Tabriz, Iran
基金
美国国家卫生研究院;
关键词
Computational drug repurposing; COVID-19; SARS-CoV-2; Docking and molecular dynamics; Structure-guided machine learning; Virus-host interaction network analysis; CORONAVIRUS; DOCKING; COMPLEMENT; SARS-COV-2; KNOWLEDGE; HELICASE; DATABASE; BINDING; DESIGN;
D O I
10.1016/j.drudis.2021.07.026
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The COVID-19 pandemic has caused millions of deaths and massive societal distress worldwide. Therapeutic solutions are urgently needed, but de novo drug development remains a lengthy process. One promising alternative is computational drug repurposing, which enables the prioritization of existing compounds through fast in silico analyses. Recent efforts based on molecular docking, machine learning, and network analysis have produced actionable predictions. Some predicted drugs, targeting viral proteins and pathological host pathways are undergoing clinical trials. Here, we review this work, highlight drugs with high predicted efficacy and classify their mechanisms of action. We discuss the strengths and limitations of the published methodologies and outline possible future directions. Finally, we curate a list of COVID-19 data portals and other repositories that could be used to accelerate future research.
引用
收藏
页码:2800 / 2815
页数:16
相关论文
共 50 条
  • [1] REPURPOSED DRUGS FOR TREATMENT AGAINST COVID-19
    Dwivedi, Jayati
    Singh, Vishal K.
    Raj, Rupa
    Singh, Ramendra K.
    EVERYMANS SCIENCE, 2021, 56 (3-4): : 95 - 100
  • [2] Repurposed Drugs Against COVID-19: Safety Concerns and Stockout
    Khan, Jehan Zeb
    Ali, Iftikhar
    Hassan, Zair
    HOSPITAL PHARMACY, 2020, 55 (04) : 218 - 219
  • [3] Perspective: repurposed drugs for COVID-19
    Na-Bangchang, Kesara
    Porasuphatana, Supatra
    Karbwang, Juntra
    ARCHIVES OF MEDICAL SCIENCE, 2022, 18 (05) : 1378 - 1391
  • [4] Repurposed GI Drugs in the Treatment of COVID-19
    Enrik John T. Aguila
    Ian Homer Y. Cua
    Digestive Diseases and Sciences, 2020, 65 : 2452 - 2453
  • [5] Repurposed GI Drugs in the Treatment of COVID-19
    Aguila, Enrik John T.
    Cua, Ian Homer Y.
    DIGESTIVE DISEASES AND SCIENCES, 2020, 65 (08) : 2452 - 2453
  • [6] Repurposed Drugs Failed to Prevent Severe COVID-19
    Slomski, Anita
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 328 (12): : 1171 - 1171
  • [7] An Overview of Repurposed Drugs for Potential COVID-19 Treatment
    Govender, Kamini
    Chuturgoon, Anil
    ANTIBIOTICS-BASEL, 2022, 11 (12):
  • [8] Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment
    Martinez, Miguel Angel
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [9] Impact of repurposed drugs on the symptomatic COVID-19 patients
    Hussain, Iqbal
    Hussain, Afzal
    Alajmi, Mohamed F.
    Rehman, Md Tabish
    Amir, Samira
    JOURNAL OF INFECTION AND PUBLIC HEALTH, 2021, 14 (01) : 24 - 38
  • [10] Evaluating the comparative effectiveness and safety of repurposed drugs for COVID-19
    Tan, Eng Hooi
    Dawoud, Dalia
    Arshad, Faaizah
    Lane, Jennifer
    Weaver, James
    Duarte-Salles, Talita
    DuVall, Scott
    Falconer, Thomas
    Kostka, Kristin
    Lynch, Kristine
    Matheny, Michael
    Reich, Christian
    Rijnbeek, Peter
    Hripcsak, George
    Schuemie, Martijn
    Ryan, Patrick
    Prieto-Alhambra, Daniel
    Suchard, Marc
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 25 - 26